ANGPTL3 and coronary artery disorder: In addition, ANGPTL3 LOF mutations prevent CAD without serious adverse health consequences and are expressed predominantly in hepatocytes, several features that make nucleic acid therapy potentially more effective than monoclonal antibodies.